生长分化因子-9在人膀胱癌组织中的表达及其临床意义

目的：探讨生长分化因子-9（growth differentiation factor-9，GDF-9）在人膀胱癌组织中的表达及其与膀胱癌病理分级和临床分期的关系。方法：运用免疫组化技术检测GDF-9在50例不同分期分级的膀胱癌组织和15例正常膀胱组织之间的蛋白表达情况。结果：①正常人膀胱组织中GDF-9呈高表达，且GDF-9蛋白主要定位于膀胱移行上皮细胞的胞浆中。而膀胱癌组织中GDF-9呈低表达或不表达。②GDF-9阳性表达率在膀胱癌病理分级间分别：I级47．6％（10／21），II级26．7％（4／15），III级7．1％（1／14），差异具有统计学意义（P〈0．05）。GDF9阳性表达率在膀胱癌临床分期间分别：Ta～T1期40．6％（13／32），T2～T3期11．1％（2／18），差异具有统计学意义（P％0．05）。结论：GDF-9在膀胱癌组织中低表达或不表达，且与膀胱癌病理分级和临床分期呈负相关。GDF-9可能是一个潜在的人膀胱肿瘤抑癌基因。

Expression and its clinical significance of growth differentiation factor-9 in bladder cancer

Objective： To investigate the expression of growth differentiation factor-9 （GDF-9） in bladder transitional cell carcinoma （BTCC） and its clinical significance in the malignancy of BTCC. Method： Immunohistochemical methods was used to detect GDF-9 protein in 50 cases of BTCC and 15 cases of normal bladder muscosa served as the controls. Result： In normal bladder tissues, stronger staining of GDF 9 was seen in transitional cells, both in the cytoplasm and in the nucleus. In contrast, the staining of GDF-9 was notably weak or absent in cancer cells of tumour tissues. The positive expression rate of GDF9 in Grade I , II and III according to pathological grade of BTCC was 47. 6% （10/21）, 26. 7G （4/15） and 7. 1% （1/14）, respectively. There were significant differences among the three pathological grades. The positive expression rate of GDF9 in Stage Ta-T1 and T2-T3 according to clinical stages of BTCC was 40.6G （13/32） and 11.1%（2/18）, respectively. There were significant differences between the two clinical stages. Conclusion： GDF-9 is expressed at lower levels in human bladder cancer tissues compared with normal transitional cells of the bladder. GDF-9 levels are inversely correlated with the path ological grade and clinical stages of bladder cancer. It suggests that GDF-9 is a potential turnout suppressor in human bladder cancer.